BioLineRx Ltd. Reports Annual Shareholder Meeting Results
Ticker: BLRX · Form: 6-K · Filed: Oct 1, 2024 · CIK: 1498403
Sentiment: neutral
Topics: shareholder-meeting, corporate-governance
TL;DR
BioLineRx held its shareholder meeting Oct 1, results are in.
AI Summary
BioLineRx Ltd. announced the results of its Annual General Meeting of Shareholders held on October 1, 2024. The meeting took place at 3:00 p.m. Israel time, and the company confirmed the outcomes of the votes cast by its shareholders.
Why It Matters
This filing provides transparency on corporate governance and shareholder decisions, which can impact investor confidence and the company's strategic direction.
Risk Assessment
Risk Level: low — This is a routine corporate filing announcing the results of an annual general meeting, with no new financial or operational risks disclosed.
Key Players & Entities
- BioLineRx Ltd. (company) — Registrant
- October 1, 2024 (date) — Date of Annual General Meeting
FAQ
What was the purpose of the Form 6-K filing?
The Form 6-K filing was made by BioLineRx Ltd. to report the results of its Annual General Meeting of Shareholders held on October 1, 2024.
When was the Annual General Meeting of Shareholders held?
The Annual General Meeting of Shareholders was held on October 1, 2024, at 3:00 p.m. Israel time.
What is the principal executive office address of BioLineRx Ltd.?
The principal executive offices of BioLineRx Ltd. are located at 2 HaMa’ayan Street, Modi’in 7177871, Israel.
Does BioLineRx Ltd. file annual reports under Form 20-F or Form 40-F?
BioLineRx Ltd. files its annual reports under cover of Form 20-F.
What is the Commission file number for BioLineRx Ltd.?
The Commission file number for BioLineRx Ltd. is 001-35223.
Filing Stats: 440 words · 2 min read · ~1 pages · Grade level 12.4 · Accepted 2024-10-01 16:15:22
Filing Documents
- zk2432094.htm (6-K) — 11KB
- 0001178913-24-003201.txt ( ) — 12KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. BioLineRx Ltd. By: /s/ Philip A. Serlin Philip A. Serlin Chief Executive Officer Dated: October 1, 2024